Clinical trial
Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to…
NCT00120848 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00120848 |
|---|---|
| Title | Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults |
| Official title | Study of the Efficacy of Candidate HPV 16/18 VLP Vaccine in the Prevention of HPV-16 and/or HPV-18 Cervical Infection in Adolescent & Young Adult Women in North America and Brazil Vaccinated in Primary Study 580299/001 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Infections, Papillomavirus |
| Intervention type | Biological |
| Interventions | HPV 16/18 VLP AS04 |
| Enrollment | 776 |
| Start date | Nov 1, 2003 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Jul 19, 2005 |
| Last update posted | Nov 4, 2016 |
| Countries | Brazil, Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: